Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-course chemoradiotherapy plus adebrelimab and apatinib as neoadjuvant therapy for rectal cancer
ChiCTR2600127564Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in rectal cancer, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Complete response rate (including clinical complete response and pathologic complete response). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2600127564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127564.